SCHEMBL7045989

SCHEMBL7045989

COc1nn(-c2ccc(NC(=O)C(C)(C)C)c(C)c2)c(=O)o1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 4/20 0.66
FAAH O00519 3/20 0.66
LPL P06858 1/20 0.53
LIPC P11150 1/20 0.53
LIPE Q05469 1/20 0.53
ABHD16A O95870 2/20 0.50
TP53 P04637 1/20 0.42
ABHD6 Q9BV23 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
MITF O75030 1/20 0.36
HPGD P15428 1/20 0.36
KLF5 Q13887 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7571649 0.90 MGLL (0.72) MGLLFAAHLPLLIPCLIPE
SCHEMBL7656723 0.84 MGLL (0.62) MGLLFAAHLPLLIPCLIPE
SCHEMBL7656177 0.83 MGLL (0.61) MGLLFAAHLPLLIPCLIPE
SCHEMBL6615026 0.83 MGLL (0.75) MGLLFAAHLPLLIPCLIPE
SCHEMBL7046042 0.82 MGLL (0.72) MGLLFAAHLPLLIPCLIPE
SCHEMBL7046095 0.82 MGLL (0.74) MGLLFAAHLPLLIPCLIPE
SCHEMBL7046445 0.81 MGLL (0.62) MGLLFAAHLPLLIPCLIPE
SCHEMBL7042329 0.80 MGLL (0.61) MGLLFAAHLPLLIPCLIPE
SCHEMBL7047530 0.79 MGLL (0.60) MGLLFAAHLPLLIPCLIPE
SCHEMBL7042914 0.79 MGLL (1.00) MGLLFAAHLPLLIPCLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885LPL 1845/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885LPL 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.